Is
MBRX- The Best Biotech with the most upside Potential
Just announced a major breakthrough in its effort to develop a new cancer treatment that selectively kills highly resistant tumors. Company has a relatively small OS under 25 Mil and float under 15 Mil . The company is working with the most prestigious cancer centers to treat a broader range of the most difficult cancers like pancreatic cancer. There is a huge unmet medical need in treating these hard to treat cancers and
MBRX break through with STAT3 inhibitors is a game-changer for treating cancer patients.
As thing progress I expect this to have 5-10x potential in the relative short term and possible a 50x + in the long term..
One you might want to research and stick away in your IRA ..
As i write this stock is 2.05 , recent offer was done ar 2.10 so you know institutional savy investors see major upside and are getting involved at these levels..
Just announced a major breakthrough in its effort to develop a new cancer treatment that selectively kills highly resistant tumors. Company has a relatively small OS under 25 Mil and float under 15 Mil . The company is working with the most prestigious cancer centers to treat a broader range of the most difficult cancers like pancreatic cancer. There is a huge unmet medical need in treating these hard to treat cancers and
As thing progress I expect this to have 5-10x potential in the relative short term and possible a 50x + in the long term..
One you might want to research and stick away in your IRA ..
As i write this stock is 2.05 , recent offer was done ar 2.10 so you know institutional savy investors see major upside and are getting involved at these levels..
註釋
Recent Covid Cure news could really be a game changer here.Stock still under 54 MiL Shares and potential treatment for coronavirus.
finance.yahoo.com/news/moleculin-announces-active-compound-wp1122-113000553.html
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。